OrthoPediatrics Corp. (KIDS) – What Are Brokerages Thinking About This Stock?

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $26.50.

A number of analysts have issued reports on the company. Needham & Company LLC lifted their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. BTIG Research reiterated a “buy” rating and issued a $29.00 price target on shares of OrthoPediatrics in a research report on Monday, September 14th. Truist Financial raised shares of OrthoPediatrics to a “hold” rating in a report on Thursday, October 1st. Finally, Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th.

Insiders Place Their Bets

In other OrthoPediatrics news, major shareholder Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the transaction, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David R. Pelizzon sold 326,700 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the sale, the director directly owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,100,000 shares of company stock worth $46,747,931. 32.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of OrthoPediatrics during the 2nd quarter worth $24,347,000. Granahan Investment Management LLC raised its holdings in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares during the period. Wasatch Advisors LP raised its holdings in shares of OrthoPediatrics by 56.6% during the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares during the period. AIGH Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter worth $5,161,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of OrthoPediatrics in the second quarter valued at $4,636,002. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Stock Performance

KIDS opened at $23.84 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The stock’s 50-day moving average price is $23.02 and its 200 day moving average price is $20.11. OrthoPediatrics has a 12-month low of $14.42 and a 12-month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. As a group, research analysts expect that OrthoPediatrics will post -1.14 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. Headquartered in Warsaw, Indiana, the company designs implants and instruments intended to address the distinct anatomical and clinical needs of pediatric patients, including those whose bones are still growing.

Its product portfolio includes systems for pediatric trauma and deformity correction, scoliosis treatment, limb reconstruction, and pediatric sports medicine.